CRISCITIELLO, CARMEN

CRISCITIELLO, CARMEN  

Dipartimento di Oncologia ed Emato-Oncologia  

Mostra records
Risultati 1 - 20 di 95 (tempo di esecuzione: 0.0 secondi).
Titolo Data di pubblicazione Autori Tipo File Abstract
A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer 2-gen-2019 Viale, GiuliaCriscitiello, CarmenCurigliano, Giuseppe + Article (author) -
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer 1-gen-2018 C. CriscitielloG. CuriglianoG. Pruneri + Article (author) -
Adjuvant trastuzumab in elderly with HER-2 positive breast cancer : a systematic review of randomized controlled trials 1-gen-2013 G. CuriglianoC. Criscitiello + Article (author) -
Adjuvant treatment of early male breast cancer 1-gen-2020 Crimini E.Criscitiello C.Trapani D.Curigliano G. + Article (author) -
Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: a randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine 1-giu-2015 G. CuriglianoM. AlcalayC. CriscitielloG. Viale + Article (author) -
Antibody–drug conjugates in solid tumors: a look into novel targets 1-dic-2021 Criscitiello C.Morganti S.Curigliano G. Article (author) -
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials 1-dic-2020 Viale G.Pruneri G.Vingiani A.Criscitiello C.Curigliano G.Hartman J.Shi L.Savas P. + Article (author) -
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors : a Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group : Part 1 : Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research 1-gen-2017 G. PruneriA. VingianiG. VialeC. CriscitielloG. Curigliano + Article (author) -
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents 1-gen-2020 Pricolo P.Signorelli G.Criscitiello C.Bellomi M.Curigliano G. + Article (author) -
Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars : a physician survey in the united states and emerging markets 1-gen-2014 C. CriscitielloG. Curigliano + Article (author) -
Benefit of adjuvant chemotherapy in patients with lobular breast cancer : A systematic review of the literature and metanalysis 9-apr-2021 Trapani, DCrimini, EBellerba, FCriscitiello, CCurigliano, G + Article (author) -
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer : a systematic review 1-giu-2021 Trapani, DGiugliano, FUliano, JFerraro, ECriscitiello, CCurigliano, G + Article (author) -
Best management of locally advanced inoperable breast cancer 1-gen-2013 G. CuriglianoC. Criscitiello + Article (author) -
Biopsy confirmation of metastatic sites in breast cancer patients : clinical impact and future perspectives 1-gen-2014 C. CriscitielloG. Curigliano + Article (author) -
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis 1-mar-2021 Morganti S.Zagami P.Buccimazza G.Venetis K.Mazzarella L.Viale G.Fusco N.Criscitiello C.Curigliano G. + Article (author) -
Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management 1-giu-2021 Konstantinos VenetisRoberto PiciottiElham SajjadiStefania MorgantiCarmen CriscitielloNicola Fusco + Article (author) -
Breast conservation following neoadjuvant therapy for breast cancer in the modern era : are we losing the opportunity? 1-gen-2016 C. CriscitielloG. CuriglianoG. Viale + Article (author) -
Cardiotoxicity of anticancer treatments : epidemiology, detection, and management 1-gen-2016 G. CuriglianoD. CardinaleC. Criscitiello + Article (author) -
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines 1-gen-2012 Curigliano, G.Criscitiello, C. + Article (author) -
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer 19-feb-2018 D. TrapaniG. VialeC. CriscitielloD'AMICO, PAOLOL. MazzarellaG. CuriglianoACHUTTI DUSO, BRUNO + Article (author) -